Raić-Malić S, Hergold-Brundić A, Nagl A, Grdisa M, Pavelić K, De Clercq E, Mintas M
Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, Marulicev trg 20, P.O. Box 177, HR-10000 Zagreb, Croatia.
J Med Chem. 1999 Jul 15;42(14):2673-8. doi: 10.1021/jm991017z.
The novel pyrimidine derivatives 1-6 of 2,3-dibenzyl-4,5-didehydro-5, 6-dideoxy-L-ascorbic acid were synthesized by the condensation of pyrimidine bases with 5,6-diacetyl-2,3-dibenzyl-L-ascorbic acid (DDA). Both N-9 (7) and N-7 (8) regioisomers were obtained in the reaction of 6-chloropurine with 5-acetyl-6-bromo-2, 3-dibenzyl-L-ascorbic acid (ABDA), while the reaction of 6-(N-pyrrolyl)purine with ABDA afforded exclusively the N-9 isomer 9. Structures of all newly prepared compounds were deduced from the chemical shifts in (1)H and (13)C NMR spectra, as well as connectivities in 2D homo- and heteronuclear correlation spectra. An unambiguous proof of the structure and conformation of 7 was obtained by X-ray crystallographic analysis. Compounds 1-9 were found to exert cytostatic activities against malignant cell lines: pancreatic carcinoma (MiaPaCa2), breast carcinoma (MCF7), cervical carcinoma (HeLa), laryngeal carcinoma (Hep2), murine leukemia (L1210/0), murine mammary carcinoma (FM3A), and human T-lymphocytes (Molt4/C8 and CEM/0), as well as antiviral activities against varicella-zoster virus (TK(+)VZV and TK(-)VZV) and cytomegalovirus (CMV). The compound 6 containing a trifluoromethyl-substituted uracil ring exhibited marked antitumor activity. The N-7-substituted purine regioisomer 8 had greater inhibitory effects on the murine L1210/0 and human CEM/0 cell lines than the N-9 isomer 7. Compound 9 with the 6-purine-substituted pyrrolo moiety had a more pronounced selective cytostatic activity against human (Molt4/C8 and CEM/0) cell lines than murine (L1210/0 and FM3A/0) and human (MiaPaCa2, MCF7, HeLa, and Hep2) tumor cell lines and normal fibroblasts (Hef522). The compound 6 exhibited the most potent antiviral activities against TK(+)VZV, TK(-)VZV, and CMV, albeit at concentrations that were only slightly lower than the cytotoxic concentrations.
通过嘧啶碱与5,6 - 二乙酰基 - 2,3 - 二苄基 - L - 抗坏血酸(DDA)缩合反应合成了新型的2,3 - 二苄基 - 4,5 - 二脱氢 - 5,6 - 二脱氧 - L - 抗坏血酸的嘧啶衍生物1 - 6。6 - 氯嘌呤与5 - 乙酰基 - 6 - 溴 - 2,3 - 二苄基 - L - 抗坏血酸(ABDA)反应得到了N - 9(7)和N - 7(8)区域异构体,而6 - (N - 吡咯基)嘌呤与ABDA反应仅得到N - 9异构体9。所有新制备化合物的结构通过¹H和¹³C NMR谱中的化学位移以及二维同核和异核相关谱中的连接关系推导得出。通过X射线晶体学分析获得了7的结构和构象的明确证据。发现化合物1 - 9对恶性细胞系具有细胞生长抑制活性,这些细胞系包括:胰腺癌(MiaPaCa2)、乳腺癌(MCF7)宫颈癌(HeLa)、喉癌(Hep2)、小鼠白血病(L1210/0)、小鼠乳腺癌(FM3A)以及人T淋巴细胞(Molt4/C8和CEM/0),并且对水痘 - 带状疱疹病毒(TK(+)VZV和TK(-)VZV)和巨细胞病毒(CMV)具有抗病毒活性。含有三氟甲基取代尿嘧啶环的化合物6表现出显著的抗肿瘤活性。N - 7取代的嘌呤区域异构体8对小鼠L1210/0和人CEM/0细胞系的抑制作用比N - 9异构体7更强。具有6 - 嘌呤取代吡咯部分的化合物9对人(Molt4/C8和CEM/0)细胞系的选择性细胞生长抑制活性比小鼠(L1210/0和FM3A/0)以及人(MiaPaCa2、MCF7、HeLa和Hep2)肿瘤细胞系和正常成纤维细胞(Hef522)更为显著。化合物6对TK(+)VZV、TK(-)VZV和CMV表现出最强的抗病毒活性,尽管其浓度仅略低于细胞毒性浓度。